Comparative Pharmacology
Head-to-head clinical analysis: DOXY 200 versus MINOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 200 versus MINOCYCLINE HYDROCHLORIDE.
DOXY 200 vs MINOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
Bacteriostatic antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
200 mg orally once daily or 100 mg orally every 12 hours.
200 mg orally or intravenously once, followed by 100 mg every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life: 11–17 hours (mean ~15 hours in normal renal function); prolonged to 18–30 hours in renal impairment; context: allows twice-daily dosing, but accumulation can occur in hepatic/renal dysfunction.
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Renal (approximately 10% unchanged; higher in impaired renal function), biliary/fecal (major route via feces as unchanged drug and metabolites, up to 70% overall elimination through hepatobiliary system).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic